莱特莫韦

莱特莫韦（CAS 917389-32-3）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in recipients, ≥6 months of age and ≥6 kg, of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in kidney transplant recipients, ≥12 years of age and ≥40 kg, who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegative).Letermovir is an antiviral agent which targets the DNA terminal transferase complex of the cytomegalovirus (CMV) and which is used to prevent CMV reactivation in immunocompromised patients. Letermovir has been associated with mild-to-moderate serum aminotransferase elevations during therapy but has not been linked to cases of clinically apparent acute liver injury.

同义词与商品名

Letermovir; 917389-32-3; Prevymis; AIC246; AIC-246; AIC 246; MK-8228; 1H09Y5WO1F; DTXSID40238683; letermovirum; RefChem:57199; DTXCID90161174; J05AX18; 805-689-9; UNII-1H09Y5WO1F; MFCD22572725

GHS 危害分类

Reported hazard statements	H361 (97.2%), H373 (100%)

H361 (97.2%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

H373 (100%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

公开数据库对它的描述

Letermovir · CAS 917389-32-3 · C29H28F4N4O4. UNII 1H09Y5WO1F.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。